Hightower Advisors Stake in Edwards Lifesciences (EW) Has Lifted by $6.94 Million as Shares Rose; As Sabre (SABR) Valuation Rose, Shareholder Vulcan Value Partners Trimmed Holding

December 20, 2017 - By Stephen Andrade

Vulcan Value Partners Llc decreased its stake in Sabre Corp (SABR) by 0.37% based on its latest 2017Q2 regulatory filing with the SEC. Vulcan Value Partners Llc sold 40,747 shares as the company’s stock rose 7.09% with the market. The institutional investor held 10.92 million shares of the programming company at the end of 2017Q2, valued at $237.76 million, down from 10.96M at the end of the previous reported quarter. Vulcan Value Partners Llc who had been investing in Sabre Corp for a number of months, seems to be less bullish one the $5.64 billion market cap company. The stock increased 1.89% or $0.38 during the last trading session, reaching $20.53. About 1.11M shares traded. Sabre Corporation (NASDAQ:SABR) has declined 17.80% since December 20, 2016 and is downtrending. It has underperformed by 34.50% the S&P500.

Hightower Advisors Llc increased its stake in Edwards Lifesciences Corp (EW) by 251.75% based on its latest 2017Q2 regulatory filing with the SEC. Hightower Advisors Llc bought 58,804 shares as the company’s stock rose 25.80% with the market. The institutional investor held 82,162 shares of the industrial specialties company at the end of 2017Q2, valued at $9.71M, up from 23,358 at the end of the previous reported quarter. Hightower Advisors Llc who had been investing in Edwards Lifesciences Corp for a number of months, seems to be bullish on the $24.16B market cap company. The stock decreased 0.15% or $0.17 during the last trading session, reaching $114.15. About 963,514 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since December 20, 2016 and is uptrending. It has underperformed by 1.29% the S&P500.

Analysts await Sabre Corporation (NASDAQ:SABR) to report earnings on February, 6. They expect $0.22 EPS, down 12.00% or $0.03 from last year’s $0.25 per share. SABR’s profit will be $60.46M for 23.33 P/E if the $0.22 EPS becomes a reality. After $0.29 actual EPS reported by Sabre Corporation for the previous quarter, Wall Street now forecasts -24.14% negative EPS growth.

Investors sentiment increased to 1.75 in 2017 Q2. Its up 0.59, from 1.16 in 2017Q1. It increased, as 28 investors sold SABR shares while 64 reduced holdings. 75 funds opened positions while 86 raised stakes. 312.30 million shares or 6.76% more from 292.51 million shares in 2017Q1 were reported. Point72 Asia (Hong Kong) Ltd owns 3,056 shares or 0.07% of their US portfolio. 126,551 are owned by Westwood Gp. Bain Credit Lp holds 9.74% or 788,175 shares. Bancorporation Of Montreal Can holds 0.01% or 634,234 shares in its portfolio. Boston Private Wealth Limited Liability Com accumulated 690,984 shares or 0.59% of the stock. 83,171 are owned by Apg Asset Mngmt Nv. River Road Asset Mgmt Ltd Liability Corporation reported 0.34% stake. Art Llc owns 158,300 shares for 0.18% of their portfolio. Herndon Management Lc owns 1,709 shares for 0.01% of their portfolio. Ameriprise Fin holds 0.01% or 868,670 shares. Moreover, Dekabank Deutsche Girozentrale has 0% invested in Sabre Corporation (NASDAQ:SABR) for 12,427 shares. Invesco Ltd accumulated 2.28M shares. Brinker Capital Inc has invested 0.02% in Sabre Corporation (NASDAQ:SABR). The Alabama-based Oakworth Cap has invested 0% in Sabre Corporation (NASDAQ:SABR). 229,105 were reported by Markston Intll Limited Liability.

Vulcan Value Partners Llc, which manages about $6.07 billion and $11.22B US Long portfolio, upped its stake in Cardinal Health Inc (NYSE:CAH) by 66,247 shares to 4.36 million shares, valued at $339.53 million in 2017Q2, according to the filing. It also increased its holding in United Technologies Corp (NYSE:UTX) by 209,443 shares in the quarter, for a total of 563,496 shares, and has risen its stake in Boeing Co (NYSE:BA).

Among 12 analysts covering Sabre Corporation (NASDAQ:SABR), 8 have Buy rating, 1 Sell and 3 Hold. Therefore 67% are positive. Sabre Corporation had 22 analyst reports since July 21, 2015 according to SRatingsIntel. Sterne Agee CRT initiated it with “Buy” rating and $33 target in Wednesday, April 13 report. The firm has “Outperform” rating given on Wednesday, August 5 by Oppenheimer. The firm has “Buy” rating given on Thursday, June 1 by Oppenheimer. The rating was maintained by Oppenheimer on Tuesday, July 25 with “Buy”. The stock of Sabre Corporation (NASDAQ:SABR) earned “Buy” rating by Cowen & Co on Thursday, October 12. The rating was maintained by Mizuho on Wednesday, February 8 with “Buy”. Goldman Sachs downgraded Sabre Corporation (NASDAQ:SABR) on Monday, September 11 to “Neutral” rating. On Wednesday, June 1 the stock rating was upgraded by SunTrust to “Buy”. The rating was downgraded by Bank of America on Tuesday, February 14 to “Neutral”. Pacific Crest initiated the shares of SABR in report on Thursday, March 31 with “Overweight” rating.

Hightower Advisors Llc, which manages about $15.08 billion and $11.55B US Long portfolio, decreased its stake in Fidelity (FNCL) by 41,121 shares to 65,011 shares, valued at $2.38M in 2017Q2, according to the filing. It also reduced its holding in New Mtn Fin Corp (NYSE:NMFC) by 30,171 shares in the quarter, leaving it with 87,174 shares, and cut its stake in Prudential Finl Inc (NYSE:PRU).

Among 27 analysts covering Edwards Lifesciences Corp (NYSE:EW), 20 have Buy rating, 1 Sell and 6 Hold. Therefore 74% are positive. Edwards Lifesciences Corp had 90 analyst reports since July 30, 2015 according to SRatingsIntel. On Tuesday, September 22 the stock rating was initiated by UBS with “Buy”. BTIG Research maintained the shares of EW in report on Wednesday, July 27 with “Buy” rating. The rating was maintained by RBC Capital Markets on Friday, September 1 with “Buy”. On Thursday, March 17 the stock rating was initiated by Nomura with “Buy”. Cowen & Co maintained it with “Outperform” rating and $120 target in Wednesday, April 27 report. The firm has “Overweight” rating given on Wednesday, July 27 by Morgan Stanley. Guggenheim initiated Edwards Lifesciences Corporation (NYSE:EW) on Thursday, June 9 with “Neutral” rating. Citigroup maintained the stock with “Sell” rating in Wednesday, April 27 report. The rating was maintained by Canaccord Genuity on Wednesday, November 29 with “Buy”. The firm earned “Outperform” rating on Monday, April 4 by Leerink Swann.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts